{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:52:44Z","timestamp":1779378764930,"version":"3.53.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["252300420144"],"award-info":[{"award-number":["252300420144"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bmc.2026.118585","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:09:53Z","timestamp":1770077393000},"page":"118585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of novel olaparib-\u03b2-carboline hybrids for treating BRCA-deficient triple negative breast cancer"],"prefix":"10.1016","volume":"136","author":[{"given":"Xiaojuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118585_bb0005","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118585_bb0010","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/cancers12040916","article-title":"The landscape of targeted therapies in TNBC","volume":"12","author":"Vagia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118585_bb0015","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: Futureoutlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bmc.2026.118585_bb0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.bmc.2026.118585_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118585_bb0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2026.118585_bb0035","doi-asserted-by":"crossref","first-page":"10502","DOI":"10.1074\/jbc.TM118.000371","article-title":"How cells ensure correct repair of DNA double-strand breaks","volume":"293","author":"Her","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1097-2765(00)80276-2","article-title":"Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells","volume":"2","author":"Chen","year":"1998","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2026.118585_bb0045","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/bjc.2011.382","article-title":"The role of PARP in DNA repair and its therapeutic exploitation","volume":"105","author":"Javle","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2026.118585_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bmc.2026.118585_bb0055","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1078-0432.CCR-20-2766","article-title":"PARP inhibitors in Cancer diagnosis and therapy","volume":"27","author":"Chan","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.bmc.2026.118585_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114090","article-title":"BRCA1 deficiency in triple-negative breast cancer: protein stability as a basis for therapy","volume":"158","author":"Choi","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2026.118585_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.813457","article-title":"BRCA1 and breast Cancer: molecular mechanisms and therapeutic strategies","volume":"10","author":"Fu","year":"2022","journal-title":"Front Cell Develop Biol"},{"key":"10.1016\/j.bmc.2026.118585_bb0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bmc.2026.118585_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2026.118585_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2026.118585_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113688","article-title":"A comprehensive overview of \u03b2-carbolines and its derivatives as anticancer agents","volume":"224","author":"Luo","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113321","article-title":"\u03b2-Carbolines as potential anticancer agents","volume":"216","author":"Aaghaz","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jphotobiol.2010.05.005","article-title":"Beta-carboline alkaloids bind DNA","volume":"100","author":"Nafisi","year":"2010","journal-title":"J Photochem Photobiol B"},{"key":"10.1016\/j.bmc.2026.118585_bb0100","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cbi.2016.08.025","article-title":"Spectroscopic and structural studies on the interaction of an anticancer \u03b2-carboline alkaloid, harmine with GC and AT specific DNA oligonucleotides","volume":"260","author":"Sharma","year":"2016","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.bmc.2026.118585_bb0105","doi-asserted-by":"crossref","first-page":"16099","DOI":"10.1021\/acs.jmedchem.2c01352","article-title":"Multi-therapies based on PARP inhibition: potential therapeutic approaches for Cancer treatment","volume":"65","author":"Zhang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0110","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/1535-7163.MCT-20-0932","article-title":"CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate Cancer to PARP inhibition","volume":"20","author":"Lawrence","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118585_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.610205","article-title":"Alkannin-induced oxidative DNA damage synergizes with PARP inhibition to cause Cancer-specific cytotoxicity","volume":"11","author":"Chang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2026.118585_bb0120","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1038\/s41388-020-1191-x","article-title":"Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells","volume":"39","author":"Wang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2026.118585_bb0125","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bmcl.2016.09.054","article-title":"Design, synthesis and biological activity of novel molecules designed to target PARP and DNA","volume":"27","author":"Goodfellow","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118585_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1054616","article-title":"Discovery of a potent olaparib-chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer","volume":"13","author":"Qin","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2026.118585_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109035","article-title":"Olaparib-Cediranib hybrid as dual PARP-VEGFR3 inhibitor elicits antitumor efficacy: rational design, synthesis, biological evaluation and construction of a charge convertible pH responsive Nanoformulation","volume":"165","author":"Rana","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0140","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1016\/j.bmc.2017.05.058","article-title":"Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy","volume":"25","author":"Yuan","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114574","article-title":"Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone","volume":"240","author":"Kayumov","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.105458","article-title":"Development of biotin decorated Olaparib loaded cationic lipopolymeric hybrid nanoparticle and evaluation of its anticancer effect and pharmacokinetics for triple negative breast cancer","volume":"94","author":"Pradhan","year":"2024","journal-title":"J Drug Delivery Sci Technol"},{"key":"10.1016\/j.bmc.2026.118585_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118227","article-title":"Discovery of novel \u03b2-carboline\/melatonin hybrids as STAT3 inhibitors for the treatment of lung cancer via increasing DNA damage","volume":"127","author":"Yang","year":"2025","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0160","doi-asserted-by":"crossref","first-page":"10054","DOI":"10.1002\/slct.201902419","article-title":"Iodine-DMSO-catalyzed chemoselective biomimetic aromatization of tetrahydro-\u03b2-carbolines-3-carboxylic acid: mechanism study with DFT-calculation","volume":"4","author":"Gaikwad","year":"2019","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bmc.2026.118585_bb0165","series-title":"Preparation of Small Molecule Inhibitors of the CRL4 Ubiquitin Ligase, WO2023173136 A2","author":"Zhou","year":"2023"},{"key":"10.1016\/j.bmc.2026.118585_bb0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ejmech.2017.12.055","article-title":"Synthesis of podophyllotoxin linked \u03b2-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors","volume":"144","author":"Sathish","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0175","first-page":"1170","article-title":"Synthesis, antileishmanial activity and spin labeling EPR studies of novel \u03b2-carboline-oxazoline and \u03b2-carboline-dihydrooxazine derivatives","volume":"31","author":"Barea","year":"2020","journal-title":"J Braz Chem Soc"},{"key":"10.1016\/j.bmc.2026.118585_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111919","article-title":"Discovery of novel phosphatidylcholine-specific phospholipase C drug-like inhibitors as potential anticancer agents","volume":"187","author":"Eurtivong","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0185","doi-asserted-by":"crossref","first-page":"16680","DOI":"10.1021\/acs.jmedchem.3c01326","article-title":"1,3-substituted \u03b2-Carboline derivatives as potent chemotherapy for the treatment of cystic echinococcosis","volume":"66","author":"Chen","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0190","doi-asserted-by":"crossref","first-page":"7973","DOI":"10.1021\/acs.jmedchem.4c00030","article-title":"A \u03b2-Carboline derivate PAD4 inhibitor reshapes neutrophil phenotype and improves the tumor immune microenvironment against triple-negative breast Cancer","volume":"67","author":"Zhu","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0195","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1134\/S1070428016110117","article-title":"Dehydrogenation of 1-aryl(hetaryl)-1,2,3,4-tetrahydro-9H-\u03b2-carboline-3-carboxylic acids and their esters with dimethyl sulfoxide","volume":"52","author":"Abramyants","year":"2016","journal-title":"Russ J Org Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0200","doi-asserted-by":"crossref","unstructured":"Shaaban, S., Abdullah, K.T., Shalabi, K., Yousef, T.A., Al Duaij, O.K., Alsulaim, G.M, Althikrallah, H.A., Alaasar, M., Al-Janabi, A.S.M., Abu-Dief, A.M., 2024. Synthesis, structural characterization, anticancer, antimicrobial, antioxidant, and computational assessments of zinc(II), Iron(II), and copper(II) chelates derived from Selenated Schiff Base. Appl Organomet Chem, 38, e7712. doi:https:\/\/doi.org\/10.1002\/aoc.7712.","DOI":"10.1002\/aoc.7712"},{"key":"10.1016\/j.bmc.2026.118585_bb0205","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.3390\/ma15103678","article-title":"Synthesis, spectroscopic, structural and molecular docking studies of some new Nano-sized ferrocene-based imine chelates as antimicrobial and anticancer agents","volume":"15","author":"Khalaf","year":"2022","journal-title":"Materials"},{"key":"10.1016\/j.bmc.2026.118585_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70190","article-title":"Leveraging the fragment merging approach for synthetizing novel Selanyl phenyl Acetamide thiazolidinedione hybrids endowed with apoptotic potential for Cancer treatment","volume":"86","author":"Shaaban","year":"2025","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.bmc.2026.118585_bb0215","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.2174\/0109298673319340240809104237","article-title":"Organoselenium-based Azomethines as apoptosis inducers in colorectal carcinoma via P53, BAX, Caspase-3, Caspase-6, and Caspase-9 modulations","volume":"32","author":"Shaaban","year":"2025","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2026.118585_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.70118","article-title":"Harnessing fragment merging and chain extension approaches for designing Phthalimidoalkyl-Arylidene thiazolidinedione hybrids: new Frontiers in apoptosis-inducing Cancer treatment","volume":"358","author":"Shaaban","year":"2025","journal-title":"Arch Pharm"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626000416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626000416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T10:37:56Z","timestamp":1775385476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626000416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"alternative-id":["S0968089626000416"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118585","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel olaparib-\u03b2-carboline hybrids for treating BRCA-deficient triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118585"}}